Inhibition of autophagy: Phase I safety, tolerability, and pharmacokinetics (PK) of hydroxychloroquine (H) in combination with vorinostat (V) in patients with advanced solid tumors.
Devalingam Mahalingam(The University of Texas at San Antonio Health Science Center), Francis J. Giles(National University of Ireland), Jennifer S. Carew(University of Arizona), John Sarantopoulos(St. Boniface Hospital), Steffan T. Nawrocki(University of Arizona), Tyler J. Curiel(Tulane University), Leslie Wood(The University of Texas System), Alain C. Mita(Cedars-Sinai Medical Center), Monica Mita(Novartis (Switzerland)), Athanassios Argiris(The University of Texas at San Antonio Health Science Center)
Cited by 0
Related Papers
Early Results of a Chemoimmunotherapy Regimen of Fludarabine, Cyclophosphamide, and Rituximab As Initial Therapy for Chronic Lymphocytic Leukemia
|Journal of Clinical Oncology|2005|951
Survivin: Key Regulator of Mitosis and Apoptosis and Novel Target for Cancer Therapeutics
|Clinical Cancer Research|2008|782
Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high‐risk myelodysplastic syndrome:
|Cancer|2006|607
Interventions to Slow Aging in Humans: Are We Ready?
|Aging Cell|2015|598